Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma
The multiple myeloma rivalry between Sanofi and J&J continued Wednesday evening, with the French drugmaker’s Sarclisa taking home a new approval in the indication.
US regulators OK’d the drug in combination with Amgen’s Kyprolis and the steroid dexamethasone for adults with relapsed or refractory multiple myeloma who have received between one and three previous lines of treatment. It’s the second approval for Sarclisa, having previously won a green light in March 2020 as a third-line treatment for the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.